期刊文献+
共找到298篇文章
< 1 2 15 >
每页显示 20 50 100
Emodin regulating excision repair cross-complementation group 1 through fibroblast growth factor receptor 2 signaling 被引量:3
1
作者 Gang Chen Hong Qiu +3 位作者 Shan-Dong Ke Shao-Ming Hu Shi-Ying Yu Sheng-Quan Zou 《World Journal of Gastroenterology》 SCIE CAS 2013年第16期2481-2491,共11页
AIM: To investigate the molecular mechanisms underlying the reversal effect of emodin on platinum resistance in hepatocellular carcinoma. METHODS: After the addition of 10 μmol/L emodin to HepG2/oxaliplatin (OXA) cel... AIM: To investigate the molecular mechanisms underlying the reversal effect of emodin on platinum resistance in hepatocellular carcinoma. METHODS: After the addition of 10 μmol/L emodin to HepG2/oxaliplatin (OXA) cells, the inhibition rate (IR), 50% inhibitory concentration (IC 50 ) and reversal index (IC 50 in experimental group/IC 50 in control group) were calculated. For HepG2, HepG2/OXA, HepG2/OXA/T, each cell line was divided into a control group, OXA group, OXA + fibroblast growth factor 7 (FGF7) group and OXA + emodin group, and the final concentrations of FGF7, emodin and OXA in each group were 5 ng/mL, 10 μg/mL and 10 μmol/L, respectively. Single-cell gel electrophoresis was conducted to detect DNA damage, and the fibroblast growth factor receptor 2 (FGFR2), phosphorylated extracellular signal-regulated kinase 1/2 (p-ERK1/2) and excision repair cross-complementing gene 1 (ERCC1) protein expression levels in each group were examined by Western blotting. RESULTS: Compared with the IC50 of 120.78 μmol/L in HepG2/OXA cells, the IC 50 decreased to 39.65 μmol/L after treatment with 10 μmol/L emodin; thus, the reversal index was 3.05. Compared with the control group, the tail length and Olive tail length in the OXA group, OXA + FGF7 group and OXA + emodin group were significantly increased, and the differences were statistically significant (P < 0.01). The tail length and Olive tail length were lower in the OXA + FGF7 group than in the OXA group, and this difference was also statistically significant. Compared with the OXA + FGF7 group, the tail extent, the Olive tail moment and the percentage of tail DNA were significantly increased in the OXA + emodin group, and these differences were statistically significant (P < 0.01). In comparison with its parental cell line HepG2, the HepG2/OXA cells demonstrated significantly increased FGFR2, p-ERK1/2 and ERCC1 expression levels, whereas the expression of all three molecules was significantly inhibited in HepG2/ OXA/T cells, in which FGFR2 was silenced by FGFR2 shRNA. In the examined HepG2 cells, the FGFR2, p-ERK1/2 and ERCC1 expression levels demonstrated increasing trends in the OXA group and OXA + FGF7 group. Compared with the OXA group and OXA + FGF7 group, the FGFR2, p-ERK1/2, and ERCC1 expression levels were significantly lower in the OXA + emodin group, and these differences were statistically significant. In the HepG2/OXA/T cell line that was transfected with FGFR2 shRNA, the FGFR2, p-ERK1/2 and ERCC1 expression levels were significantly inhibited, but there were no significant differences in these expression levels among the OXA, OXA + FGF7 and OXA + emodin groups. CONCLUSION: Emodin markedly reversed OXA resistance by enhancing OXA DNA damage in HepG2/OXA cells, and the molecular mechanism was related to the inhibitory effect on ERCC1 expression being mediated by the FGFR2/ERK1/2 signaling pathway. 展开更多
关键词 HEPATOCELLULAR carcinoma EMODIN FIBROBLAST growth factor receptor 2 excision repair crosscomplementation group 1 Platinum resistance EXTRACELLULAR SIGNAL-REGULATED kinase
在线阅读 下载PDF
Tea polyphenols increase X-ray repair cross-complementing protein 1 and apurinic/apyrimidinic endonuclease/redox factor-1 expression in the hippocampus of rats during cerebral ischemia/reperfusion injury
2
作者 Zhi Wang Rongliang Xue +8 位作者 Xi Lei Jianrui Lv Gang Wu Wei Li Li Xue Xiaoming Lei Hongxia Zhao Hui Gao Xin Wei 《Neural Regeneration Research》 SCIE CAS CSCD 2012年第30期2355-2361,共7页
Recent studies have shown that tea polyphenols can cross the blood-brain barrier, inhibit apoptosis and play a neuroprotective role against cerebral ischemia. Furthermore, tea polyphenols can decrease DNA damage cause... Recent studies have shown that tea polyphenols can cross the blood-brain barrier, inhibit apoptosis and play a neuroprotective role against cerebral ischemia. Furthermore, tea polyphenols can decrease DNA damage caused by free radicals. We hypothesized that tea polyphenols repair DNA damage and inhibit neuronal apoptosis during global cerebral ischemia/reperfusion. To test this hypothesis, we employed a rat model of global cerebral ischemia/reperfusion. We demonstrated that intraperitoneal injection of tea polyphenols immediately after reperfusion significantly reduced apoptosis in the hippocampal CA1 region; this effect started 6 hours following reperfusion. Immunohistochemical staining showed that tea polyphenols could reverse the ischemia/reperfusion-induced reduction in the expression of DNA repair proteins, X-ray repair cross-complementing protein 1 and apudnic/apyrimidinic endonuclease/redox factor-1 starting at 2 hours. Both effects lasted at least 72 hours. These experimental findings suggest that tea polyphenols promote DNA damage repair and protect against apoptosis in the brain. 展开更多
关键词 global cerebral ischemia/reperfusion X-ray repair cross-complementing protein 1 apurinic/apyrimidinic endonuclease/redox factor-I tea polyphenols
在线阅读 下载PDF
ERCC1、K-ras、TP-73在替雷利珠单抗联合TP化疗方案治疗非小细胞肺癌中的评估价值 被引量:2
3
作者 王亚飞 张振军 +1 位作者 宋长亮 杨琼 《标记免疫分析与临床》 CAS 2024年第3期496-501,共6页
目的研究探讨核苷酸切除修复交叉互补基因1(ERCC1)、Kirsten-Rous肉瘤病毒蛋白(K-ras)、肿瘤蛋白P73(TP73)在替雷利珠单抗结合紫杉醇+顺铂(TP)化疗方案治疗NSCLC中的评估价值。方法选取2020年1月至2021年12月本院收治的126例NSCLC肺癌... 目的研究探讨核苷酸切除修复交叉互补基因1(ERCC1)、Kirsten-Rous肉瘤病毒蛋白(K-ras)、肿瘤蛋白P73(TP73)在替雷利珠单抗结合紫杉醇+顺铂(TP)化疗方案治疗NSCLC中的评估价值。方法选取2020年1月至2021年12月本院收治的126例NSCLC肺癌患者为研究对象,按随机抽签法分为对照组、观察组,各63例。对照组以TP化疗方案治疗,观察组增加替雷利珠单抗治疗。评估组间临床疗效、肿瘤标记蛋白、免疫指标、生存周期、不良反应。结果观察组患者的客观缓解率为69.84%(44/63)高于对照组患者为52.38%(33/63),观察组疾病控制率为82.54%(52/63),高于对照组患者为66.67%(42/63)(P<0.05)。化疗1周期、化疗3周期、化疗6周期时,观察组ERCC1、K-ras、TP-73水平均低于对照组(P<0.05)。治疗后观察组免疫功能补体C3、补体C4、CD40细胞低于对照组,NK细胞高于对照组(P<0.05)。观察组患者的TTP、PFS、总生存期均高于对照组(P<0.05)。观察组不良反应发生率为19.05%(12/63),对照组为12.70%(8/63),组间比较差异无统计学意义(P>0.05)。结论替雷利珠单抗联合TP化疗方案治疗肺癌有良好的治疗效果,能够改善患者免疫功能,延长患者生存周期,治疗安全性较好,且ERCC1、K-ras、TP-73水平变化可反映替雷利珠单抗联合TP化疗方案在肺癌治疗中的效果,在综合疗效评估中有较高的应用价值。 展开更多
关键词 替雷利珠单抗 紫杉醇 顺铂 核苷酸切除修复交叉互补基因1 基因Kirsten-Rous肉瘤病毒蛋白 肿瘤蛋白P73 非小细胞肺癌
在线阅读 下载PDF
切除修复交叉互补族6-样表达与非小细胞肺癌临床病理特征的关系及其预后意义
4
作者 仇睿 刘阳 +2 位作者 马波 吕志平 马云帆 《临床外科杂志》 2025年第3期266-270,共5页
目的探讨切除修复交叉互补族6-样(Excision repair cross-complementation group 6-like,ERCC6L)在非小细胞肺癌(non-small cell lung cancer,NSCLC)中的表达特点及其预后价值。方法2016年9月~2019年收治的NSCLC组织及其癌旁组织(距癌... 目的探讨切除修复交叉互补族6-样(Excision repair cross-complementation group 6-like,ERCC6L)在非小细胞肺癌(non-small cell lung cancer,NSCLC)中的表达特点及其预后价值。方法2016年9月~2019年收治的NSCLC组织及其癌旁组织(距癌组织至少5 cm远的非肿瘤组织)144例,采用免疫组织化学(Immunohistochemistry,IHC)法检测ERCC6L蛋白在NSCLC组织及其癌旁组织中的表达。比较ERCC6L高、低表达病人的临床病理资料,生存分析采用Kaplan-Meier曲线和Cox风险比例回归模型,评估ERCC6L表达与NSCLC病人总体生存(overall survival,OS)的关系。结果IHC染色在42.4%(61/144)的NSCLC组织中检测到ERCC6L高表达,高于癌旁组织(37.7,%,37/144),差异有统计学意义(χ^(2)=8.909,P<0.05)。ERCC6L高表达在低分化癌(χ^(2)=38.660,P<0.001)、T2/T3期(χ^(2)=6.528,P=0.011)和TNMⅢ期肿瘤(χ^(2)=12.522,P<0.05)中更为常见,且淋巴结转移(χ^(2)=5.802,P<0.05)、淋巴血管侵犯(χ^(2)=29.899,P<0.05)与胸膜侵犯(χ^(2)=7.942,P<0.05)较低表达者更为频繁,差异有统计学意义(P<0.05)。生存分析显示与低表达组比较,ERCC6L高表达病人的OS明显更短,5年OS率分别为44.8%和70.5%,差异有统计学意义(χ^(2)=15.919,P<0.05)。单、多变量Cox回归分析表明,ERCC6L高表达(HR=2.106,95%CI=1.087~4.079,P<0.05)是NSCLC病人的独立预后因素。结论ERCC6L在NSCLC中的高表达与肿瘤侵袭性特征密切相关,或许是NSCLC病人一项有价值的预后分子标志物。 展开更多
关键词 非小细胞肺癌 切除修复交叉互补族6- 免疫组织化学 肿瘤侵袭性 预后标志物
在线阅读 下载PDF
Impact of SNP-SNP interactions of DNA repair gene ERCC5 and metabolic gene GSTP1 on gastric cancer/atrophic gastritis risk in a Chinese population 被引量:5
5
作者 Liang Sang Zhi Lv +2 位作者 Li-Ping Sun Qian Xu Yuan Yuan 《World Journal of Gastroenterology》 SCIE CAS 2018年第5期602-612,共11页
AIM To investigate the interactions of the DNA repair gene excision repair cross complementing group 5(ERCC5) and the metabolic gene glutathione S-transferase pi 1(GSTP1) and their effects on atrophic gastritis(AG) an... AIM To investigate the interactions of the DNA repair gene excision repair cross complementing group 5(ERCC5) and the metabolic gene glutathione S-transferase pi 1(GSTP1) and their effects on atrophic gastritis(AG) and gastric cancer(GC) risk.METHODS Seven ERCC5 single nucleotide polymorphisms(SNPs)(rs1047768, rs2094258, rs2228959, rs4150291, rs4150383, rs751402, and rs873601) and GSTP1 SNP rs1695 were detected using the Sequenom MassA RRAY platform in 450 GC patients, 634 AG cases, and 621 healthy control subjects in a Chinese population.RESULTS Two pairwise combinations(ERCC5 rs2094258 and rs873601 with GSTP1 rs1695) influenced AG risk(P_(interaction) = 0.008 and 0.043, respectively), and the ERCC5 rs2094258-GSTP1 rs1695 SNP pair demonstrated an antagonistic effect, while ERCC5 rs873601-GSTP1 rs1695 showed a synergistic effect on AG risk OR = 0.51 and 1.79, respectively). No pairwise combinations were observed in relation to GC risk. There were no cumulative effects among the pairwise interactions(ERCC5 rs2094258 and rs873601 with GSTP1 rs1695) on AG susceptibility(P_(trend) > 0.05). When the modification effect of Helicobacter pylori(H. pylori) infection was evaluated, the cumulative effect of one of the aforementioned pairwise interactions(ERCC5 rs873601-GSTP1 rs1695) was associated with an increased AG risk in the case of negative H. pylori status(P_(trend)= 0.043).CONCLUSION There is a multifarious interaction between the DNA repair gene ERCC5 SNPs(rs2094258 and rs873601) and the metabolic gene GSTP1 rs1695, which may form the basis for various inter-individual susceptibilities to AG. 展开更多
关键词 excision repair cross complementing group 5 Glutathione S-TRANSFERASE pi 1 ATROPHIC GASTRITIS Gastric cancer Single nucleotide polymorphisms
在线阅读 下载PDF
DNA repair gene XRCC1 polymorphisms and susceptibility to childhood acute lymphoblastic leukemia: a meta-analysis 被引量:4
6
作者 Juan Du Cong Lu +2 位作者 Guohui Cui Yan Chen Jing He 《Chinese Journal of Cancer Research》 SCIE CAS CSCD 2013年第4期405-415,共11页
Objective: To estimate the relationship between genetic polymorphisms of X-ray repair cross- complementing group 1 (XRCC1) and the susceptibility to childhood acute lymphoblastic leukemia (ALL). Methods: Relevan... Objective: To estimate the relationship between genetic polymorphisms of X-ray repair cross- complementing group 1 (XRCC1) and the susceptibility to childhood acute lymphoblastic leukemia (ALL). Methods: Relevant case-control studies were enrolled in the meta-analysis. We applied Rev Man 4.2 software to pool raw data and test studies' heterogeneity and to calculate the incorporated odds ratio (OR) and 95% confidence interval (95% CI). Results: Our data showed that the OR for the Gln allele of the Arg399Gln polymorphism, compared with the Arg allele, was 1.35 (95% CI, 1.16-1.57; P〈0.0001) for childhood ALL patients. Similarly, the homozygous genotype Gln/Gln and heterozygous genotype Arg/Gln both significantly increased the risk of childhood ALL compared with the wild genotype Arg/Arg (OR =1.58; 95% CI, 1.13-2.21; P=0.008; OR =1.51; 95% CI, 1.21-1.87; P=0.0002). The dominant model of Arg399Gln was associated with childhood ALL risk (OR =1.54; 95% CI, 1.25-1.89; P〈0.0001). The ethnic subgroup analysis demonstrated that the Gln allele in all five ethnic groups was prone to be a risk factor for childhood ALL just with different degrees of correlation while Arg194Trp SNP showed a protective or risk factor or irrelevant thing in different races. Conclusions: XRCC1 399 polymorphism may increase the risk of childhood ALL. Different ethnic groups with some gene polymorphism have different disease risks. 展开更多
关键词 X-ray repair cross-complementing group 1 (XRCC1 gene polymorphism CHILDHOOD acute lymphoblastic leukemia (ALL)
在线阅读 下载PDF
人脑胶质瘤组织中ERCC1、ARL2表达水平与患者病理特征、预后的关系
7
作者 陈恒三 郭超 +7 位作者 王虎 魏祎 金明 于向阳 黄铭 周东春 尚银武 路安庆 《中华神经外科疾病研究杂志》 2025年第2期45-49,共5页
目的探讨人脑胶质瘤(BG)组织中核苷酸切除修复交叉互补基因1(ERCC1)、ADP核糖基化样因子2(ARL2)表达水平与患者病理特征、预后的关系。方法选取2019年8月至2022年8月期间甘肃省人民医院收治的122例BG患者,将手术过程中取得的BG肿瘤组织... 目的探讨人脑胶质瘤(BG)组织中核苷酸切除修复交叉互补基因1(ERCC1)、ADP核糖基化样因子2(ARL2)表达水平与患者病理特征、预后的关系。方法选取2019年8月至2022年8月期间甘肃省人民医院收治的122例BG患者,将手术过程中取得的BG肿瘤组织标本纳入BG组(n=122),将同期因颅脑外伤而获取的正常脑组织标本纳入对照组(n=60)。采用免疫组化法检测ERCC1、ARL2在脑组织中的表达情况;通过χ2检验分析ERCC1、ARL2表达与BG临床病理特征的关系;采用多因素Cox回归分析探讨BG患者预后的影响因素。结果BG组ERCC1、ARL2的阳性表达率为69.67%、66.39%,高于对照组的28.33%、25.00%(P<0.05)。低分化BG患者的ERCC1阳性表达率、ARL2阳性表达率高于中/高分化患者(P<0.05)。122例BG患者出院后连续随访2年,59例存活,总生存率为48.36%(59/122)。中/高分化、ERCC1阴性、ARL2阴性患者的2年总生存率分别高于低分化、ERCC1阳性、ARL2阳性患者(P均<0.05)。低分化(HR=2.368,95%CI:1.442~3.888)、ERCC1阳性(HR=2.824,95%CI:1.634~4.879)、ARL2阳性(HR=3.370,95%CI:1.902~5.973)是BG患者预后的独立危险因素(P<0.05)。结论ERCC1、ARL2在BG患者脑组织中呈高表达,分化程度越低其表达水平越高,且ERCC1、ARL2与患者术后生存期有一定关联性。 展开更多
关键词 人脑胶质瘤 核苷酸切除修复交叉互补基因1 ADP核糖基化样因子2 预后
在线阅读 下载PDF
Neuronal effects of SP600125 pretreatment in a rat model of cerebral ischemia/reperfusion injury Inhibited down-regulation of DNA repair protein 被引量:1
8
作者 Ning Wang Rongliang Xue +4 位作者 Fengzhen Yao Jiaxuan He Jianrui Lu Pengbo Zhang Gang Wu 《Neural Regeneration Research》 SCIE CAS CSCD 2009年第12期1055-1061,共7页
BACKGROUND: Recent studies have shown that the selective inhibitor of c-Jun N-terminal kinases (JNKs) signaling pathway, SP600125, exhibits neuronal protective effects in a rat model of brain ischemia/reperfusion. ... BACKGROUND: Recent studies have shown that the selective inhibitor of c-Jun N-terminal kinases (JNKs) signaling pathway, SP600125, exhibits neuronal protective effects in a rat model of brain ischemia/reperfusion. OBJECTIVE: To determine the mechanisms of neuroprotective effects of SP600125 in a rat model of brain ischemia/reperfusion, and determine the role of the JNK signaling pathway in SP600125-induced effects. DESIGN, TIME AND SETTING: A randomized, controlled, animal experiment was performed at the Animal Experiment Center, Medical School of Xi'an Jiaotong University from June 2007 to September 2008. MATERIALS: SP600125 was provided by Biosource, USA; rabbit anti-phospho-JNK (Thr183/Tyr185) polyclonal antibody from Cell Signaling Technology, USA; rabbit anti-X-ray repair cross-complementing protein 1 (XRCC1) and anti-Ku70 polyclonal antibodies from Santa Cruz Biotechnology, USA; and TUNEL kit from Beijing Huamei Biology, China. METHODS: A total of 108 male, 4-month-old, Sprague Dawley rats were randomly assigned to three groups, with 36 rats per group. The sham operation group and ischemia/reperfusion group (I/R group) were intracerebroventricularly injected with 10 μL 1% DMSO. The SP600125-treated group (pre-SP group) was given 10 μL SP600125 (3 μg/μL). Thirty minutes later, brain ischemia was induced in the I/R and pre-SP groups using the four-vessel occlusion method. Specifically, whole brain ischemia was induced for 6 minutes, and the clips were released to restore carotid artery blood flow. Rats from each group were observed at 2, 6, 12, 24, 48, and 72 hours, with 6 rats for each time point. The sham operation group was treated with the same surgical exposure procedures, with exception of occlusion of the carotid artery. MAIN OUTCOME MEASURES: Hematoxylin-eosin staining was used to observe neuronal survival in the hippocampal CA1 region, TUNEL was used to detect apoptosis in the hippocampal CA1 region, and immunohistochemistry was used to detect expression of phospho-JNK, XRCC1, and Ku70. RESULTS: Following brain ischemia/reperfusion, neuronal survival significantly decreased, and the number of apoptotic cells significantly increased (P 〈 0.01). Compared with the I/R group, neuronal survival significantly increased in the pre-SP group, and the number of apoptotic cells significantly decreased (P 〈 0.01). Expression of phospho-JNK increased, and XRCC1 and Ku70 significantly decreased (P 〈 0.05) following ischemia/reperfusion. Compared with the I/R group, expression of phospho-JNK decreased, and XRCC1 and Ku70 significantly increased in the pre-SP group (P 〈 0.05). Correlation analysis revealed an inverse correlation between phospho-JNK gray value and XRCC1 and Ku70 gray values in the hippocampal CA1 region (r = -0.983, -0.953, P 〈 0.01). CONCLUSION: SP600125 treatment decreased apoptosis induced by global brain ischemia/reperfusion in the rat hippocampal CA1 region. Results suggested that the neuroprotective effects were due to inhibited phosphorylation of JNK and reduced down-regulation of XRCC1 and Ku70. 展开更多
关键词 ischemia/reperfusion injury apoptosis c-Jun N-terminal kinases DNA repair protein X-ray repair cross-complementing protein 1 KU70
在线阅读 下载PDF
Excision repair cross complementation group 1 polymorphisms and lung cancer risk: a meta-analysis 被引量:9
9
作者 CAO Chao ZHANG Yan-mei +7 位作者 WANG Ran SUN Shi-fang CHEN Zhong-bo MA Hong-ying YU Yi-ming DING Qun-li SHU Li-hua DENG Zai-chun 《Chinese Medical Journal》 SCIE CAS CSCD 2011年第14期2203-2208,共6页
Background Several studies have evaluated the association between polymorphisms of encoding excision repair cross complementation group 1 (ERCC1) enzyme and lung cancer risk in diverse populations but with conflicti... Background Several studies have evaluated the association between polymorphisms of encoding excision repair cross complementation group 1 (ERCC1) enzyme and lung cancer risk in diverse populations but with conflicting results.By pooling the relatively small samples in each study, it is possible to perform a meta-analysis of the evidence by rigorous methods.Methods Embase, Ovid, Medline and Chinese National Knowledge Infrastructure were searched. Additional studies were identified from references in original studies or review articles. Articles meeting the inclusion criteria were reviewed systematically, and the reported data were aggregated using the statistical techniques of meta-analysis.Results We found 3810 cases with lung cancer and 4332 controls from seven eligible studies. T19007C polymorphism showed no significant effect on lung cancer risk (C allele vs. T allele: odds ratio (OR)=0.91, 95% confidence interval (CI)=0.80-1.04; CC vs. TT: OR=0.76, 95% CI=0.56-1.02; CC vs. (CT+TT): OR=0.96, 95% CI=-0.84-1.10). Similarly,there was no significant main effects for T19007C polymorphism on lung cancer risk when stratified analyses by ethnicity (Chinese or Caucasian). No significant association was found between C8092A polymorphism (3060 patients and 2729 controls) and the risk of lung cancer (A allele vs. C allele: OR=1.03, 95% CI=0.95-1.11; AA vs. CC: OR=1.08, 95% CI=-0.88-1.33; AA vs. (AC+CC): OR=1.08, 95% CI=-0.88-1.31).Conclusion We found little evidence of an association between the T1900C or C8092A polymorphisms of ERCC 1 and the risk of lung cancer in Caucasian or Han Chinese people. 展开更多
关键词 excision repair cross complementation group 1 POLYMORPHISM lung cancer SUSCEPTIBILITY META-ANALYSIS
原文传递
ERCC1表达与Ⅰ-ⅢA NSCLC患者术后生存及顺铂耐药的相关性 被引量:9
10
作者 王慧敏 张伟 +9 位作者 韩宝惠 沈洁 顾爱琴 姜丽岩 陈玉蓉 金波 张雪艳 何卫中 沙慧芳 冯久贤 《上海交通大学学报(医学版)》 CAS CSCD 北大核心 2008年第9期1072-1077,共6页
目的分析Ⅰ-ⅢA期非小细胞肺癌(NSCLC)的切除修复交叉互补组1(ERCC1)表达水平与患者术后生存期的关系,探讨ERCC1表达与患者预后及顺铂耐药的相关性。方法收集1992年2月~1994年1月及2002~2005年经根治性手术并获长期随访的152例Ⅰ... 目的分析Ⅰ-ⅢA期非小细胞肺癌(NSCLC)的切除修复交叉互补组1(ERCC1)表达水平与患者术后生存期的关系,探讨ERCC1表达与患者预后及顺铂耐药的相关性。方法收集1992年2月~1994年1月及2002~2005年经根治性手术并获长期随访的152例Ⅰ-ⅢA期NSCLC患者的临床资料。Ⅰ期NSCLC患者术后随机分成不化疗组和化疗组;Ⅱ、ⅢA期术后均采用以顺铂为主的联合化疗方案。免疫组化法检测所有肿瘤组织标本的ERCCl表达。Kaplan—Meier法计算生存率,Log—rank检验比较差异性,并行Cox模型多因素分析。结景I期NSCLC患者ERCC1高表达者,不论化疗与否其预后都明显好于ERCCl低表达者。其中ERCC1高表达组1、3、5年生存率分别为100.00%、9t.30%、86.74%,低表达组则为96.43%、60.71%、57.14%(P=0.0058)。不同于Ⅰ期NSCLC,Ⅱ~ⅢA期NSCLC术后化疗患者ERCC低表达则有较好预后。其中Ⅱ期ERCC1低表达者中位生存期(MST)为60.0+月,而高表达者仅为25.5月(P=0.0442);ⅢA期ERCC1低表达组MST为41个月,高表达组仅为24个月(P=0.0203)。结论ERCC1表达对Ⅰ-ⅢANSCLC术后患者生存的影响存在双相效应。在Ⅰ期NSCLC中,ERCC1高表达是预后良好的独立指标;而对Ⅱ-ⅢA期NSCLC术后化疗患者,ERCC1高表达更多体现的是对铂类耐药;故采用铂类为基础的辅助化疗可能将无助提高术后长期生存。 展开更多
关键词 切除修复交叉互补组1 非小细胞肺癌 预后 耐药性
在线阅读 下载PDF
晚期非小细胞肺癌组织中ERCC-1、Metallothionein、p53表达与铂类耐药性及预后的相关性分析 被引量:17
11
作者 黄培钰 梁小曼 +3 位作者 林素瑕 罗荣臻 侯景辉 张力 《癌症》 SCIE CAS CSCD 北大核心 2004年第7期845-850,共6页
背景与目的晚期非小细胞肺癌含顺铂方案化疗敏感性分子预测指标尚处于探索阶段。本研究分析晚期非小细胞肺癌石蜡包埋组织中错配切除修复蛋白(excisionrepaircrosscomplement-1,ERCC-1)、金属硫蛋白(metallothionein,MT)、p53蛋白与顺... 背景与目的晚期非小细胞肺癌含顺铂方案化疗敏感性分子预测指标尚处于探索阶段。本研究分析晚期非小细胞肺癌石蜡包埋组织中错配切除修复蛋白(excisionrepaircrosscomplement-1,ERCC-1)、金属硫蛋白(metallothionein,MT)、p53蛋白与顺铂化疗敏感性的关系,并观察这些指标与病人生存的关系。方法收集1994年1月-2001年12月在本院经病理组织学诊断的用含铂方案(Gemzar+DDP或NVB+DDP)化疗的初治晚期非小细胞肺癌患者的病理标本,采用免疫组化方法检测ERCC-1、MT、p53的表达,并将病人的疗效和生存资料与上述指标的表达进行比较。样本率的比较用χ2检验,用Kaplan-meier法和Cox回归进行生存分析。结果本组51例标本中,ERCC-1阳性率为42.8%,MT阳性率为57.5%,p53阳性率为37.8%。化疗有效率在ERCC-1、MT、p53阴性组和阳性组分别为33.3%、35.3%、21.4%和16.7%、27.3%、35.3%(即分别为1.99倍,1.29倍,0.61倍),但均未达统计学差异(P>0.05),ERCC-1,MT均阴性组有效率为37.5%,均阳性组有效率为14.3%,前者为后者的2.6倍,但未达统计学差异(P>0.05)。平均生存期ERCC-1、MT、p53蛋白阴性组和阳性组分别为621.03天/523.14天,556天/479天,599.64天/416.60天。Kaplan-meier分析显示三者过度表达均提示预后不良,但Cox回归分析显示只? 展开更多
关键词 非小细胞性肺癌 ERCC-1 MT p53 顺铂 耐药 预后
在线阅读 下载PDF
Excision Repair Cross-complementation Group 1 is a Prognostic Biomarker in Patients with Colorectal Cancer Receiving Chemotherapy 被引量:6
12
作者 Mu-Xing Li Xin-Yu Bi +5 位作者 Hong Zhao Zhen Huang Yue Han Dong-Bin Zhao Jian-Jun Zhao Jian-Qiang Cai 《Chinese Medical Journal》 SCIE CAS CSCD 2016年第5期586-593,共8页
Background:Conflicting results about the association between expression level of excision repair cross-complementation group 1 (ERCC1) and clinical outcome in patients with colorectal cancer (CRC) receiving chemo... Background:Conflicting results about the association between expression level of excision repair cross-complementation group 1 (ERCC1) and clinical outcome in patients with colorectal cancer (CRC) receiving chemotherapy have been reported.Thus,we searched the available articles and performed the meta-analysis to elucidate the prognostic role of ERCC1 expression in patients with CRC.Methods:A thorough literature search using PubMed (Medline),Embase,Cochrane Library,Web of Science databases,and Chinese Science Citation Database was conducted to obtain the relevant studies.Pooled hazard ratios (HRs) or odds ratios (ORs) with 95% confidence intervals (CIs) were calculated to estimate the results.Results:A total of 11 studies were finally enrolled in this meta-analysis.Compared with patients with lower ERCC1 expression,patients with higher ERCC1 expression tended to have unfavorable overall survival (OS) (HR =2.325,95% CI:1.720-3.143,P 〈 0.001),progression-free survival (PFS) (HR =1.917,95% CI:1.366-2.691,P 〈 0.001) and poor response to chemotherapy (OR =0.491,95% CI:0.243-0.990,P =0.047).Subgroup analyses by treatment setting,ethnicity,HR extraction,detection methods,survival analysis,and study design demonstrated that our results were robust.Conclusions:ERCC1 expression may be taken as an effective prognostic factor predicting the response to chemotherapy,OS,and PFS.Further studies with better study design and longer follow-up are warranted in order to gain a deeper understanding of ERCC 1's prognostic value. 展开更多
关键词 Colorectal Cancer: excision repair cross-complementation Group I PROGNOSIS
原文传递
GST-π、ERCC1、MRP和LRP在卵巢癌组织中的表达及意义 被引量:10
13
作者 梁梦 周英琼 +3 位作者 郭芳 侯巧燕 许连静 李莎莎 《中国现代医学杂志》 CAS CSCD 北大核心 2012年第5期10-14,共5页
目的探讨谷胱甘肽S-转移酶π(GST-π)、切除修复交叉互补基因(ERCC1)、多药耐药相关蛋白(MRP)及肺耐药相关蛋白(LRP)在上皮性卵巢癌组织中的表达及临床意义。方法采用免疫组织化学技术检测67例卵巢恶性肿瘤、20例卵巢良性肿瘤和16例正... 目的探讨谷胱甘肽S-转移酶π(GST-π)、切除修复交叉互补基因(ERCC1)、多药耐药相关蛋白(MRP)及肺耐药相关蛋白(LRP)在上皮性卵巢癌组织中的表达及临床意义。方法采用免疫组织化学技术检测67例卵巢恶性肿瘤、20例卵巢良性肿瘤和16例正常卵巢组织中GST-π、ERCC1、MRP及LRP的表达状况,并对相关的临床病理因素进行分析。结果①67例卵巢癌中,GST-π、MRP和LRP阳性表达均显著高于其在卵巢良性肿瘤和正常卵巢组织中的阳性表达(P<0.05),而ERCC1的阳性表达同卵巢良性肿瘤和正常卵巢组织比较差异无统计学意义(P>0.05)。②GST-π的表达与肿瘤分化程度有关,分化越低表达越高(P<0.05);而ERCC1、MRP和LRP的阳性表达与多种临床病理因素无关(P>0.05)。结论 GST-π、ERCC1、MRP及LRP蛋白在卵巢癌的发生发展及耐药机制中发挥重要作用,联合检测对卵巢癌治疗方案的合理制定及化疗反应性的评估具有积极的临床指导意义。 展开更多
关键词 卵巢癌 谷胱甘肽S-转移酶π 修复交叉互补基因1 多药耐药相关蛋白 肺耐药相关蛋白 化疗
在线阅读 下载PDF
非小细胞肺癌原发灶与转移淋巴结中MDR-1、RRM-1、EGFR、ERCC-1的表达差异 被引量:11
14
作者 郭楠楠 李珊珊 +4 位作者 张文 于长海 王宏伟 张宜明 俞建琦 《细胞与分子免疫学杂志》 CAS CSCD 北大核心 2013年第8期870-873,共4页
目的研究非小细胞肺癌(NSCLC)原发灶和转移淋巴结中多药耐药蛋白(MDR-1)、核糖核苷酸还原酶M1(RRM-1)、表皮生长因子受体(EGFR)、错配切除修复蛋白1(ERCC-1)表达的差异,并分析这些表达差异性与临床病理类型的关系。方法采用免疫组织化... 目的研究非小细胞肺癌(NSCLC)原发灶和转移淋巴结中多药耐药蛋白(MDR-1)、核糖核苷酸还原酶M1(RRM-1)、表皮生长因子受体(EGFR)、错配切除修复蛋白1(ERCC-1)表达的差异,并分析这些表达差异性与临床病理类型的关系。方法采用免疫组织化学染色观察46例NSCLC原发灶及转移淋巴结中MDR-1、RRM-1、EGFR、ERCC-1蛋白的表达情况,用Wilcoxon秩和检验来比较原发灶和淋巴结转移灶表达是否存在差异,用Fisher检验分析差异性是否与病理类型相关。结果 46例各种病理类型的NSCLC,原发病灶与转移淋巴结均存在MDR-1、RRM-1、EGFR、ERCC-1表达,其中ECRR-1的表达差异在腺癌中具有统计学意义(P=0.026),而MDR-1,RRM-1,EGFR的差异性在各病理类型无统计学意义(P>0.05)。结论 MDR-1、RRM-1、EGFR、ERCC-1在NSCLC的原发病灶和转移淋巴结中均表达,但只有ERCC-1在肺腺癌原发灶与转移淋巴结的表达具有明显差异。 展开更多
关键词 非小细胞肺癌 原发肿瘤 转移淋巴结 多药耐药蛋白 核糖核苷酸还原酶M1 表皮生长因子受体 剪切修复交叉互补基因1
在线阅读 下载PDF
天冬氨酸蛋白酶A、甲状腺转录因子-1、核苷酸切除修复交叉互补基因1检测在肺癌患者中的应用价值 被引量:4
15
作者 杜旭升 李东繁 +5 位作者 李广顺 王冠杰 柴丽丽 范亚莉 李娜苗 李建英 《实用临床医药杂志》 CAS 2020年第7期8-11,共4页
目的探讨检测天冬氨酸蛋白酶A(NapsinA)、甲状腺转录因子-1(TTF-1)、核苷酸切除修复交叉互补基因1(ERCC1)的表达在肺癌患者中的应用价值.方法选取40例肺癌患者的手术切除肺癌病理标本,以40例癌旁正常组织作为对照,检测NapsinA、TTF-1、F... 目的探讨检测天冬氨酸蛋白酶A(NapsinA)、甲状腺转录因子-1(TTF-1)、核苷酸切除修复交叉互补基因1(ERCC1)的表达在肺癌患者中的应用价值.方法选取40例肺癌患者的手术切除肺癌病理标本,以40例癌旁正常组织作为对照,检测NapsinA、TTF-1、FERCC1表达.结果肺癌组织中NapsinA、TTF-1、ERCC1表达水平、阳性率显著高于癌旁正常组织(P<0.05);不同病理类型、分化程度者NapsinA表达阳性率差异有统计学意义(P<0.05);不同病理类型、TNM分期者TTF-1表达阳性率差异有统计学意义(P<0.05);NapsinA、TTF-1、ERCC1之间无显著相关性(P>0.05).结论临床可经检测NapsinA、TTF-1、FERCC1表达判断肺癌患者病情. 展开更多
关键词 肺癌 天冬氨酸蛋白酶A 甲状腺转录因子-1 核苷酸切除修复交叉互补基因1
在线阅读 下载PDF
切除修复交叉互补基因1、核苷酸还原酶M1亚基和β-微管蛋白Ⅲ的表达对Ⅰ~Ⅲ期非小细胞肺癌术后辅助化疗疗效的预测意义 被引量:2
16
作者 石燕 陈丽 +2 位作者 李杰 吕亚莉 焦顺昌 《中国医学科学院学报》 CAS CSCD 北大核心 2010年第4期375-382,479,共9页
目的探讨切除修复交叉互补基因1(ERCC1)、核苷酸还原酶M1亚基(RRM1)和β-微管蛋白Ⅲ与接受不同辅助化疗方案的非小细胞肺癌患者预后的关系。方法回顾性分析2004年1月至2007年12月我院接受手术治疗且术后行辅助化疗的Ⅰ~Ⅲ期非小细胞肺... 目的探讨切除修复交叉互补基因1(ERCC1)、核苷酸还原酶M1亚基(RRM1)和β-微管蛋白Ⅲ与接受不同辅助化疗方案的非小细胞肺癌患者预后的关系。方法回顾性分析2004年1月至2007年12月我院接受手术治疗且术后行辅助化疗的Ⅰ~Ⅲ期非小细胞肺癌病例。利用免疫组织化学法检测ERCC1、RRM1和β-微管蛋白Ⅲ的表达,分析所有患者的临床病理特征、治疗特征、分子特征与生存规律的关系。结果 ERCC1、RRM1和β-微管蛋白Ⅲ的高表达率分别为36.4%、43.7%和38.4%,三者表达程度无相关性,ERCC1(P=0.008)和RRM1(P=0.028)在腺癌中的高表达率显著低于非腺癌,而β-微管蛋白Ⅲ在腺癌中的高表达率显著高于非腺癌(P=0.001)。所有患者中位随访时间35.8个月,80例出现复发或转移,40例死亡,中位生存期未达到,中位无疾病生存期(DFS)为24.1个月。单因素分析显示男性(P=0.036)、临床分期早(P=0.001)及非腺癌(P=0.004)患者较女性、临床分期晚及腺癌患者中位DFS显著延长,而年龄、吸烟与否、化疗方案的类型及ERCC1、RRM1和β-微管蛋白Ⅲ的表达程度对DFS无影响。分层分析显示,RRM1高表达时,含吉西他滨方案组较其他方案组DFS有缩短的趋势(P=0.054);β-微管蛋白Ⅲ高表达时,紫杉类方案组较长春瑞滨和吉西他滨组DFS有缩短的趋势(P=0.076)。而在RRM1或β-微管蛋白Ⅲ低表达以及ERCC1不同表达程度层中,各化疗方案组对DFS的影响无差异。COX多因素分析显示,腺癌与否和临床分期是影响DFS的独立预后因素。结论对于接受手术治疗及术后辅助化疗的非小细胞肺癌患者,RRM1高表达者对吉西他滨耐药,而β-微管蛋白Ⅲ高表达者对紫杉类耐药,在耐药人群中使用其他方案似乎能给患者带来更多的生存获益。免疫组织化学法检测ERCC1、RRM1和β-微管蛋白Ⅲ的表达有助于筛选辅助化疗药物及预测化疗疗效。 展开更多
关键词 非小细胞肺癌 切除修复交叉互补基因1 核苷酸还原酶M1亚基 β-微管蛋白Ⅲ 辅助化疗
在线阅读 下载PDF
海南人群中人类ERCC1-4533G/A多态性的研究 被引量:2
17
作者 蓝永洪 郑小桃 +2 位作者 蔡望伟 周代锋 林琼莲 《中国热带医学》 CAS 2006年第8期1377-1378,共2页
目的了解海南人群中人类切除修复交叉互补基因1(ERCC1)的-4533G/A多态性情况。方法用盐提取法提取人群中白细胞的DNA,以聚合酶链反应、限制性内切核酸酶检测-4533G/A多态性。结果在分析的200例海南人群中,ERCC1-4533多态性位点有GG、GA... 目的了解海南人群中人类切除修复交叉互补基因1(ERCC1)的-4533G/A多态性情况。方法用盐提取法提取人群中白细胞的DNA,以聚合酶链反应、限制性内切核酸酶检测-4533G/A多态性。结果在分析的200例海南人群中,ERCC1-4533多态性位点有GG、GA、AA3种基因型,频率分别为0.03、0.96、0.01,G和A的等位基因频率为0.51和0.49。结论ERCC1是人类核甘酸切除修复(NER)系统的重要组成部分,其表达水平与卵巢肿瘤、消化道肿瘤的耐药性有关,因此ERCC1-4533多态性的研究对于肿瘤耐药性具有重要的意义。 展开更多
关键词 切除修复交叉互补基因1 多态性 核甘酸切除修复
在线阅读 下载PDF
5-Aza-CdR通过DNMT1调控卵巢癌细胞ERCC1基因甲基化及其表达 被引量:3
18
作者 陈慧雁 李晓翠 沈宗姬 《中国肿瘤生物治疗杂志》 CAS CSCD 北大核心 2017年第6期627-631,共5页
目的:研究5-氮杂-2'-脱氧胞苷(5-Aza-CdR)在卵巢癌细胞系SKOV3中对核苷酸切除交叉修复互补基因1(excision repair cross complementation group 1,ERCC1)表达的影响及可能的机制。方法:设计特异性针对DNA甲基转移酶1(DNA methyltran... 目的:研究5-氮杂-2'-脱氧胞苷(5-Aza-CdR)在卵巢癌细胞系SKOV3中对核苷酸切除交叉修复互补基因1(excision repair cross complementation group 1,ERCC1)表达的影响及可能的机制。方法:设计特异性针对DNA甲基转移酶1(DNA methyltransferase 1,DNMT1)基因的shRNA转染入人卵巢癌细胞系SKOV3细胞中,Western blotting检测SKOV3细胞DNMT1以及ERCC1的表达变化;利用不同浓度5-Aza-CdR于不同时间点处理卵巢癌SKOV3细胞,Western blotting检测DNMT1和ERCC1蛋白在处理前后的变化,利用亚硫酸氢钠法检测ERCC1基因启动子区域甲基化水平。结果:0.5、1.0、2.0、4.0μmol/L的5-Aza-CdR作用于SKOV3细胞后,DNMT1表达水平呈浓度依赖性降低,而ERCC1表达水平呈浓度依赖性升高;使用终浓度为1.0μmol/L的5-Aza-CdR处理SKOV3细胞12、24、36 h后,DNMT1表达水平呈时间依赖性降低,而ERCC1表达水平呈时间依赖性升高,亚硫酸氢钠法检测示药物处理前ERCC1启动子区域处于高甲基化水平,在用1.0μmol/L的5-Aza-CdR处理后,其启动子发生了去甲基化。结论:5-Aza-CdR通过DNMT1调控卵巢癌SKOV3细胞中ERCC1基因的甲基化及其表达水平。 展开更多
关键词 卵巢癌 甲基化 DNA甲基转移酶1基因 切除交叉修复互补基因1
在线阅读 下载PDF
X线修复交错互补基因1-Arg399Gln多态性与宫颈癌急性放射性损伤的相关性 被引量:2
19
作者 蓝美玲 肖何 +7 位作者 余娴 张志敏 张辉 何轩 李建 周鹏 叶云飞 王阁 《第三军医大学学报》 CAS CSCD 北大核心 2016年第9期1010-1014,共5页
目的探讨X线修复交错互补基因1(X-ray repair cross complementing group 1,XRCC1)-Arg399Gln多态性与宫颈癌急性放射性损伤的相关性。方法收集经病理活检证实为宫颈癌的患者152例。Sanger测序法检测外周血XRCC1基因单核苷酸多态性(s... 目的探讨X线修复交错互补基因1(X-ray repair cross complementing group 1,XRCC1)-Arg399Gln多态性与宫颈癌急性放射性损伤的相关性。方法收集经病理活检证实为宫颈癌的患者152例。Sanger测序法检测外周血XRCC1基因单核苷酸多态性(single nucleotide polymorphism,SNP),并分析其与急性放射性损伤致放射性膀胱炎和直肠炎发生的关系。结果 152例宫颈癌患者中,携带XRCC1 Arg/Arg、Arg/Gln、Gln/Gln基因型的分别有78、56、18例。其中发生2~3级急性膀胱炎有47例;2~3级急性直肠炎有100例,没有4级膀胱炎、直肠炎的发生。对其他临床因素校正后,多变量Logistic回归分析表明XRCC1 399密码子杂合变异基因型携带者(Arg/Gln)和纯合变异携带者(Gln/Gln)的2~3级膀胱炎发生风险显著高于野生型患者,分别为野生型的4.114倍(OR=4.114,95%CI:1.746~9.693)和9.096倍(OR=9.096,95%CI:2.707~30.566);2~3级直肠炎发生风险分别是野生型的5.011倍(OR=5.011,95%CI:2.169~11.575)和7.165倍(OR=7.165,95%CI:1.506~34.092)。结论 XRCC1 399密码子的SNP与宫颈癌急性放射性膀胱炎和直肠炎有关,具有潜在的放射治疗副反应预测因子价值。 展开更多
关键词 单核苷酸多态性 X线修复交错互补基因1 宫颈癌 放疗 急性膀胱炎 急性直肠炎
在线阅读 下载PDF
乳腺癌耐药蛋白ERCC1和P-gp表达水平与新辅助化疗敏感性关系研究 被引量:1
20
作者 刘佩姿 张雁瑞 +2 位作者 罗建国 黄犁 荣磊 《吉林医学》 CAS 2017年第6期1059-1062,共4页
目的:研究耐药蛋白ERCC1和P-gp在乳腺癌中表达与临床病理特征的联系;分析ERCC1和P-gp的不同表型与新辅助化疗敏感性的相关性;探讨依据ERCC1和P-gp的不同表型制定乳腺癌化疗方案的可行性。方法:用免疫组化回顾性检测56例乳腺癌新辅助化... 目的:研究耐药蛋白ERCC1和P-gp在乳腺癌中表达与临床病理特征的联系;分析ERCC1和P-gp的不同表型与新辅助化疗敏感性的相关性;探讨依据ERCC1和P-gp的不同表型制定乳腺癌化疗方案的可行性。方法:用免疫组化回顾性检测56例乳腺癌新辅助化疗前穿刺活检留取的石蜡标本中ERCC1和P-gp的表达情况,分析两者与乳腺癌临床病理特征的关系,乳腺癌不同受体分型与化疗敏感性的关系;以及ERCC1和P-gp不同表型间新辅助化疗敏感性的差异。结果:ERCC1阳性表达率为35.7%(20/56),P-gp阳性表达率为44.6%(25/56),两者表达无明显相关性(χ~2=2.969,P=0.085)。ERCC1表达水平与肿瘤大小和TNM分期呈负相关,而P-gp则表达水平升高肿瘤分级越高。乳腺癌Luminal型、三阴性和Her-2阳性三者间比较,分别是Her-2阳性组CR率(47.1%)和三阴性pCR率(25.0%)最高,但Her-2阳性与三阴性的CR和p CR率均无统计学差异。耐药蛋白ERCC1和P-gp均为阴性者有效率(CR+PR,87.0%)最高,ERCC1阴性者有效率(72.2%)较ERCC1阳性者有效率(45.0%)高;P-gp阴性者有效率(80.6%)较P-gp阳性者有效率(40.0%)高。结论:ERCC1和P-gp是两个相对独立的耐药蛋白,两者表达阴性时乳腺癌新辅助化疗有效率更高。通过检测肿瘤组织中ERCC1和P-gp的表达情况,联合ER、PR和Her-2等分子指标,可以预测化疗敏感性和规避潜在的耐药,个体化的制定化疗方案。 展开更多
关键词 乳腺癌 切除修复交叉互补1 P糖蛋白 新辅助化疗
在线阅读 下载PDF
上一页 1 2 15 下一页 到第
使用帮助 返回顶部